BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives Consensus Rating of “Buy” from Analysts

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) has been assigned a consensus recommendation of “Buy” from the seventeen ratings firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have issued a buy rating and three have issued a strong buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $402.1429.

ONC has been the subject of a number of analyst reports. Citizens Jmp upped their price target on BeOne Medicines from $396.00 to $405.00 and gave the company a “market outperform” rating in a research report on Thursday, August 6th. Citigroup reiterated an “outperform” rating on shares of BeOne Medicines in a research report on Thursday, August 6th. Nomura raised BeOne Medicines to a “strong-buy” rating in a research note on Monday, July 27th. Wolfe Research restated an “outperform” rating and issued a $370.00 target price on shares of BeOne Medicines in a report on Monday, August 10th. Finally, Royal Bank Of Canada cut their target price on BeOne Medicines from $451.00 to $450.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th.

Insider Transactions at BeOne Medicines

In related news, COO Xiaobin Wu sold 280 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $380.00, for a total transaction of $106,400.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Titus B. Ball sold 132 shares of BeOne Medicines stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $355.86, for a total transaction of $46,973.52. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 588,481 shares of company stock valued at $192,918,836 in the last three months. 6.19% of the stock is currently owned by corporate insiders.

Institutional Trading of BeOne Medicines

Institutional investors have recently made changes to their positions in the company. EFG International AG acquired a new position in BeOne Medicines in the fourth quarter valued at approximately $25,000. Leonteq Securities AG acquired a new stake in BeOne Medicines during the fourth quarter worth $35,000. Daiwa Securities Group Inc. acquired a new stake in BeOne Medicines during the second quarter worth $35,000. CWM LLC raised its position in BeOne Medicines by 32.8% in the fourth quarter. CWM LLC now owns 158 shares of the company’s stock valued at $48,000 after purchasing an additional 39 shares during the period. Finally, Group One Trading LLC purchased a new stake in BeOne Medicines in the fourth quarter valued at $61,000. Hedge funds and other institutional investors own 48.55% of the company’s stock.

BeOne Medicines Stock Down 1.2%

Shares of NASDAQ ONC opened at $358.26 on Friday. BeOne Medicines has a 12-month low of $253.95 and a 12-month high of $385.22. The stock has a market cap of $39.33 billion, a PE ratio of 63.07 and a beta of 0.51. The company has a current ratio of 3.40, a quick ratio of 3.06 and a debt-to-equity ratio of 0.17. The company has a 50-day moving average of $333.94 and a 200 day moving average of $311.69.

BeOne Medicines (NASDAQ:ONC) last released its quarterly earnings data on Wednesday, August 5th. The company reported $2.05 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.65. BeOne Medicines had a net margin of 10.70% and a return on equity of 14.23%. The company had revenue of $1.71 billion during the quarter, compared to the consensus estimate of $1.66 billion. As a group, sell-side analysts predict that BeOne Medicines will post 8.81 EPS for the current fiscal year.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.